The protective effect of an inhibitor of the Notch pathway was associated with decreases in the expression and translocation of high mobility group Box 1 (HMGB1), cavolin-1, and inflammatory factors in vivo and in vitro, suggesting that the Notch pathway may be a potential target in nab-PTX-induced peripheral neuropathy treatment. The gene discussed is HMGB1; the disease is peripheral neuropathy.